icon-folder.gif   Conference Reports for NATAP  
  EASL 45th Annual Meeting
April 14-18, 2010
Vienna, Austria
Back grey_arrow_rt.gif
Dose-Ranging, Three-Day Monotherapy
Study of the HCV NS3 Protease Inhibitor GS-9256

  Reported by Jules Levin
EASL Apr 14-18 201
Vienna Austria
E Lawitz,1 T Marbury,2 B Vince,3 N Grunenberg,4 M Rodriguez-Torres,5 M DeMicco,6 J Tarro,7 M Shelton,8 S West,8 J Zong,8 A Bae,8 K Wong,8 H Mo,8 D Oldach,8 W Delaney,8 and F Rousseau8 1Alamo Medical Research, San Antonio, TX, USA; 2Orlando Clinical Research Center, Orlando, FL, USA; 3Vince and Associates Clinical Research, Overland Park, KS, USA; 4Charles River Clinical Services, Tacoma, WA, USA; 5Fundacion De Investigacion De Diego, Santurce, PR; 6Advanced Clinical Research Institute, Anaheim, CA, USA; 7Columbia Research Group, Portland, OR, USA; 8Gilead Sciences, Durham, NC or Foster City, CA, USA